P16、CDK4、cyclinD1在乳腺癌中的表达及临床意义

Expressions of P16，CDK4，cyclinD1 and their clinical significance in breast carcinomas

关键词:  P16  CDK4  cyclinD1  乳腺癌  细胞周期

Key words:  P16  CDK4  cyclinD1  breast cancer  cell cycle

摘要:

［目的］ 探讨P16、CDK4、cyclinD1蛋白在乳腺癌组织中的表达情况及临床意义。［方法］用免疫组织化学方法，检测32例乳腺癌组织石蜡切片P16、CDK4及cyclinD1蛋白的表达情况，并分析其与临床病理学指标之间的关系。［结果］ P16、CDK4在I级与II级、III级中的表达差异有显著性意义（P<0. 05）。P16、CDK4蛋白的阳性表达与患者的年龄、肿瘤的大小、淋巴结转移及雌激素受体（ER）、孕激素受体（PR）表达均无显著相关性。cyclinD1在I级与II级、III级中的表达差异没有显著性意义（P>0. 05），随着乳腺癌分化程度的降低，阳性表达呈现升高趋势。cyclinD1蛋白的阳性表达与患者的年龄、肿瘤的大小、淋巴结转移及ER、PR表达均无明显相关性。［结论］ P16蛋白的失表达和CDK4、cyclinD1蛋白的过表达可能参与了乳腺癌的发生和发展。

Abstract:

［Objective］ To investigate the expressions of P16, CDK4, cyclinD1 and the clinical significance of their expression in breast carcinoma. ［Methods］ The expressions of P16, CK4 and cyclinD1 were detected by immunohistochemistry in 32 cases of paraffin-embedded breast carcinoma tissues. Then, the positive rates of P16, CK4 and cyclinD1 were compared with the clinical pathological markers. ［Results］ The positive rates of P16 and CDK4 among the gradeⅠ, Ⅱand Ⅲ showed significant difference (P<0.05),indicating that the positive rate of P16 decreased along with the increase of the grade. The expression of P16 and CDK4 in the breast carcinoma didn’t show any significant relation to the patient age, tumor size,lymphatic metastasis and the presence or absence of ER, PR. The cyclinD1-positive rates in the breast carcinomas ascended as the grade increasing although they didn’t show significant difference among the gradeⅠ, Ⅱand Ⅲ(P>0.05). ［Conclusions］ The underexpression of P16 and overexpression of CK4, cyclinD1 may play a role in the initiation and development of breast carcinomas.